摘要
目的:探讨血清K19-2G2检测对肺癌的诊断价值及临床应用。方法:应用化学发光免疫分析方法检测150例肺癌患者(肺癌组)、50例肺部良性疾病患者(肺部良性疾病组)和150例健康体检者(对照组)血清K19-2G2浓度;同时检测血清CYFRA21-1浓度。结果:肺癌组血清K19-2G2浓度高于肺部良性疾病组(P<0.05)和对照组(P<0.01),K19-2G2检测肺癌的灵敏度为57.8%,特异性为99.0%,其灵敏度和特异性优于CYFRA21-1;在不同病理类型肺癌中,肺鳞癌组K19-2G2的水平明显高于其他各组,差异有统计学意义(P<0.05)。结论:K19-2G2是一种有效的非小细胞肺癌肿瘤标志物,尤其适用于肺鳞癌的诊断。
Objective To investigate the value of serum K19-2G2 assay to the diagnosis of lung cancer and its clinical application.Methods Chemiluminoimmunoassay was used to measure the serum K19-2G2 levels in 150 patients with lung cancer,50 patients with lung benign diseases and 150 normal controls,and the serum CYFRA21-1 levels were measured at same time.Results The serum K19-2G2 levels were significantly higher in lung cancer patients than those in patients with benign diseases（P0.01） and normal controls（P0.01）.The sensitivity and specificity of serum K19-2G2 detection in lung cancer were 57.8% and 99.0%,respectively,which were higher than those of CYFRA21-1.In lung cancer with different pathological types,K19-2G2 level in the squamous carcinoma group was obviously higher than that in the other groups,which showed a significant difference（P0.05）.Conclusion K19-2G2 is a useful biomarker for non-small cell lung cancer,especially for the diagnosis of squamous lung carcinoma.
出处
《中华实用诊断与治疗杂志》
2010年第7期671-673,共3页
Journal of Chinese Practical Diagnosis and Therapy
